← Leaderboards
Rodney J.y. Ho
University Of Washington
$31,444,678
Attributed
$43,802,596
Total exposure
31
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,802,596 · 31
By mechanism
UM1$15,018,645 · 1
R01$9,127,880 · 6
U01$6,697,590 · 2
R33$5,444,891 · 2
P51$4,408,719 · 16
R61$2,083,829 · 1
Top collaborators
- Ann Cornwall Collier7 shared
- Patrick Franklin Kiser5 shared
- Ann Jorns Melvin4 shared
- Hyang Nina Kim2 shared
- Rachel Ann Bender Ignacio1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Jashvant D Unadkat$14,909,800
- Hyang Nina Kim$781,005
- Peter Lindsay Anderson$21,683,918
- Candan Tamerler$519,579
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsPrimatesUnited States National Institutes Of HealthLeadDesignDoseDrug CombinationsBaseProgramsResourcesDrug Delivery SystemsDrug KineticsResearch PersonnelOralFundingTechnologyInnovationResponseUniversitiesWashingtonViralNanoparticleVirusSafety
Grant awards (62)
NextGen Long-acting and targeted combination ART for Children with HIV$1,373,809
R33 · FY2025 · AI · contact PI
Long-acting Antiviral Treatment for HBV$799,938
R01 · FY2025 · AI · contact PI
Long-acting Antiviral Treatment for HBV$762,072
R01 · FY2024 · AI · contact PI
NextGen Long-acting and targeted combination ART for Children with HIV$1,424,502
R33 · FY2023 · AI · contact PI
NextGen Long-acting and targeted combination ART for Children with HIV$1,260,148
R33 · FY2022 · AI · contact PI
Washington Entrepreneurial Research Evaluation and Commercialization Hub$994,469
U01 · FY2022 · HL · contact PI
"NextGen Long-acting Platform: Targeted Combination Antiretrovirals"$1
U01 · FY2022 · AI
NextGen Long-acting and targeted combination ART for Children with HIV$1,056,967
R61 · FY2021 · AI · contact PI
Washington Entrepreneurial Research Evaluation and Commercialization Hub$994,469
U01 · FY2021 · HL · contact PI
Washington Entrepreneurial Research Evaluation and Commercialization Hub$412,300
U01 · FY2021 · HL · contact PI
NextGen Long-acting and targeted combination ART for Children with HIV$1,026,862
R61 · FY2020 · AI · contact PI
Washington Entrepreneurial Research Evaluation and Commercialization Hub$994,469
U01 · FY2020 · HL · contact PI
"NextGen Long-acting Platform: Targeted Combination Antiretrovirals"$771,303
U01 · FY2020 · AI
Washington Entrepreneurial Research Evaluation and Commercialization Hub$744,200
U01 · FY2020 · HL · contact PI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$1,708,470
UM1 · FY2019 · AI · contact PI
Washington Entrepreneurial Research Evaluation and Commercialization Hub$991,450
U01 · FY2019 · HL · contact PI
"NextGen Long-acting Platform: Targeted Combination Antiretrovirals"$794,929
U01 · FY2019 · AI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$2,946,499
UM1 · FY2018 · AI · contact PI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$3,352,921
UM1 · FY2017 · AI · contact PI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$3,482,643
UM1 · FY2016 · AI · contact PI
Targeted Long-acting Combination Antiretroviral Therapy (TLC-ART)$3,528,112
UM1 · FY2015 · AI · contact PI
pH Responsive anti-HIV Nanoparticles$1,074,963
R01 · FY2013 · AI · contact PI
Bioresponsive Combination Microbicide Delivery System for HIV and HSV$493,043
R33 · FY2013 · AI
pH Responsive anti-HIV Nanoparticles$799,505
R01 · FY2012 · AI · contact PI
Bioresponsive Combination Microbicide Delivery System for HIV and HSV$431,949
R33 · FY2012 · AI
pH Responsive anti-HIV Nanoparticles$756,801
R01 · FY2011 · AI · contact PI
Bioresponsive Combination Microbicide Delivery System for HIV and HSV$461,440
R33 · FY2011 · AI
PRIMATE NEURO-IMAGING OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY DEVICE$377,899
P51 · FY2011 · RR · contact PI
pH Responsive anti-HIV Nanoparticles$739,995
R01 · FY2010 · AI · contact PI
CNS DRUG DELIVERY STRATEGIES TARGETING THE HIV SANCTUARY$465,257
P51 · FY2010 · RR · contact PI
TARGETING DRUG TO HIV SANCTUARY IN LYMPHATICS$310,172
P51 · FY2010 · RR · contact PI
Bioresponsive Combination Microbicide Delivery System for HIV and HSV$226,278
R21 · FY2010 · AI
pH Responsive anti-HIV Nanoparticles$100,000
R01 · FY2010 · AI · contact PI
pH Responsive anti-HIV Nanoparticles$397,744
R01 · FY2009 · AI · contact PI
TARGETING DRUG TO HIV SANCTUARY IN LYMPHATIC$331,393
P51 · FY2009 · RR · contact PI
CNS targeted delivery of anti-HIV drugs$249,356
R43 · FY2009 · MH · contact PI
Bioresponsive Combination Microbicide Delivery System for HIV and HSV$187,760
R21 · FY2009 · AI
TARGETING DRUG TO HIV SANCTUARY IN LYMPHATIC$422,135
P51 · FY2008 · RR · contact PI
CNS DRUG DELIVERY STRATEGIES TARGETING THE HIV SANCTUARY$422,135
P51 · FY2008 · RR · contact PI
CNS DRUG DELIVERY TARGETING THE HIV SANCTUARY$228,467
P51 · FY2006 · RR · contact PI
CNS specific Knock-out and Multidrug Transport$171,168
R21 · FY2006 · NS · contact PI
ANTI-HIV DRUGS TARGETING TO LYMPHOID TISSUES$164,530
P51 · FY2006 · RR · contact PI
Anti-HIV Drug Targeting to Lymphoid Tissues$714,427
R01 · FY2005 · AI
Polymorphism of Multi-Drug-Resistance Protein-1$331,031
R01 · FY2005 · GM
CNS specific Knock-out and Multidrug Transport$186,480
R21 · FY2005 · NS
ANTI-HIV DRUGS TARGETING TO LYMPHOID TISSUES$177,333
P51 · FY2005 · RR
CNS DRUG DELIVERY TARGETING THE HIV SANCTUARY$175,831
P51 · FY2005 · RR
KINETICS OF MOTHER TO FETUS HIV-2 TRANSMISSION$175,831
P51 · FY2005 · RR
Anti-HIV Drug Targeting to Lymphoid Tissues$487,178
R01 · FY2004 · AI
Polymorphism of Multi-Drug-Resistance Protein-1$321,478
R01 · FY2004 · GM
CNS DRUG DELIVERY TARGETING THE HIV SANCTUARY$228,544
P51 · FY2004 · RR
KINETICS OF MOTHER TO FETUS HIV-2 TRANSMISSION$228,544
P51 · FY2004 · RR
Anti-HIV Drug Targeting to Lymphoid Tissues$514,158
R01 · FY2003 · AI
Polymorphism of Multi-Drug-Resistance Protein-1$361,284
R01 · FY2003 · GM
CNS DRUG DELIVERY TARGETING THE HIV SANCTUARY$189,414
P51 · FY2003 · RR
KINETICS OF MOTHER TO FETUS HIV-2 TRANSMISSION$189,414
P51 · FY2003 · RR
IMMUNOGENICITY OF ENV AND/OR CORE ANTIGENS OF HIV-2$189,414
P51 · FY2003 · RR
Polymorphism of Multi-Drug-Resistance Protein-1$303,667
R01 · FY2002 · GM
MECHANISMS OF MOTHER TO FETUS HIV TRANSMISSION$0
P51 · FY2001 · RR
KINETICS &MECHANISM OF MOTHER-TO-FETUS HIV TRANSMISSION$474,077
R01 · FY2000 · HL
PHARMACOLOGIC AND BIOLOGIC STUDIES OF ANTIGEN CARRIERS$189,562
R01 · FY2000 · AI
MOTHER TO FETUS TRANSMISSION OF AIDS 2$132,406
P51 · FY2000 · RR